Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVSRIPO in Invasive Breast Cancer
NCT03564782Phase 1Completed
- Sponsor
- Istari Oncology
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lerapolturev in breast cancer, sponsored by Istari Oncology. Primary endpoint: Change in Tumor Infiltrating Immune Cells. Started Jun 2019; status: completed.
02
Drugs
lerapolturev
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03564782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564782.